Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

Oronzo Brunetti; Giuseppe Badalamenti; Simona De Summa; Angela Calabrese; Antonella Argentiero; Livia Fucci; Vito Longo; Pia Perrotti; Rosamaria Pinto; Daniela Petriella; Katia Danza; Stefania Tommasi; Francesco Leonetti; Nicola Silvestris

doi:10.20944/preprints201905.0173.v1

Maintenance Alert: Feb 8, 1:30-4:00 AM CET. Site may be unstable.

Preprint

Case Report

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

This version is not peer-reviewed.

Altmetrics

Downloads

297

Views

288

Comments

Submitted:

12 May 2019

Posted:

14 May 2019

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract

Keywords:

Subject:

Medicine and Pharmacology - Oncology and Oncogenics

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Alerts

MDPI Initiatives

Important Links

Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.

Disclaimer

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

Abstract

Keywords:

Subject:

MDPI Initiatives

Important Links

Subscribe